TX-MOBIL-1
15.3.2024 17:16:31 CET | Business Wire | Press release
To celebrate the 50th anniversary of Mobil 1™ motor oil, this year the brand will showcase more than 40 iconic, specially-designed liveries and paint schemes on the track throughout the 2024 motorsports season.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240315781564/en/
These liveries – which will be seen within IMSA, WEC, Formula 1, NASCAR, NHRA, MotoGP and more – use distinct design elements, including anniversary gold, both signifying 50 years of the Mobil 1 brand and embodying the dynamic relationships between Mobil 1 and its collaborators. Each paint scheme reflects the spirit of the Mobil 1 brand and an ongoing commitment to growing and maintaining meaningful track-to-road relationships, which is at the heart and soul of the brand.
Mobil 1 motor oils have long been the choice for preeminent race teams competing in the most demanding and popular motorsports series around the globe. Today, Mobil 1 synthetic motor oil continues to be relied upon for its ability to deliver exceptional engine performance and protection under some of the most extreme conditions. Automotive technicians, race car drivers, team owners, and some of the world’s leading automotive manufacturers can speak to the advanced technology of Mobil 1 lubricants.
“We are thrilled to bring these special paint schemes to life for such a historic anniversary of the Mobil 1 brand,” said Robert Shearer, Director of Global Sponsorships on behalf of Mobil 1. “These liveries exemplify our collaborations in lubricant innovation in the world of motorsports. Together, we’ve crafted livery designs that not only pay homage to the 50-year legacy of the Mobil 1 brand, but also capture the essence of speed, performance and teamwork. We can’t wait for fans to join us in the love of racing and witness the culmination of our collaborative efforts on the racetrack throughout the rest of the year.”
At Mobil 1 Twelve Hours of Sebring Presented by Cadillac, golden liveries will hit the track for teams and OEMs, including Vasser Sullivan Racing (Lexus Racing), Cadillac Racing, Corvette Racing by Pratt Miller Motorsports, Kellymoss with Riley (Porsche Motorsport North America), and Porsche Penske Motorsport.
With more added throughout the season, initial 50th anniversary liveries and iconography will be seen at the following upcoming race series on sponsored teams:
- Oracle Red Bull Racing (Formula 1)
- Stewart-Haas Racing (NASCAR Cup Series)
- 23XI Racing (NASCAR Cup Series)
- Tony Stewart Racing (NHRA)
- Red Bull KTM (MotoGP)
- Porsche Penske Motorsport (WEC and IMSA)
- TAG Heuer Porsche Formula E Team (Formula E)
- Mobil 1 Porsche SuperCup
- At the Pikes Peak International Hill Climb with BBI Autosport
In continuing to commemorate the 50th anniversary, fans should also look for a short film featuring former Formula 1 racer & Oracle Red Bull Racing ambassador, David Coulthard, who guides the audience through the Mobil 1 brand’s evolution, collaborations, and achievements. The video is available for viewing here.
Additional initiatives across partnerships, motorsports, and events will be shared through the year as the brand continues to celebrate its legacy and what's next. For coverage of Mobil 1 Twelve Hours of Sebring Presented by Cadillac as well as upcoming gold liveries and paint schemes, visit @mobil1racing on Instagram and X all year-long.
About Mobil 1
For 50 years, Mobil 1 has been trusted by drivers to keep their engines running longer. Our products combine the latest technology and innovation to exceed the toughest standards of vehicle manufacturers and tuning shops—so consumers can get the most out of their time behind the wheel, both on the road and on the track. Turn every day into an adventure with Mobil 1, the world’s leading synthetic motor oil brand. Learn more at www.mobil1.us or and follow @Mobil1Racing on Instagram and X. Join us. For the love of driving.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240315781564/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 09:19:00 CEST | Press release
Phase 1 study demonstrated pharmacokinetic (PK) equivalence between SB27 and Keytruda; Phase 3 study demonstrated equivalent objective response rate (ORR) at Week 24Phase 1 and Phase 3 studies expected to be completed within 2026 Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patie
IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 09:00:00 CEST | Press release
IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi
Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 09:00:00 CEST | Press release
Positive CHMP opinion is based on data from the Phase 3 RISE-PD trial, which demonstrated significantly more “Good ON” time with fewer daily doses compared with immediate-release levodopa/carbidopa More than one million people are living with Parkinson’s disease in the European Union, and over 80% experience motor fluctuations during the course of their disease, highlighting the need for additional treatment options Hopledo® contains a unique formulation combining immediate-release granules and extended-release pellets, providing both a rapid onset of action and a longer duration of effect, sustaining the levodopa therapeutic effect for a longer period of time If approved, Zambon expects to make Hopledo® progressively available to patients with Parkinson’s disease across Europe starting October 2026 Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European M
Enhertu® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors29.6.2026 08:30:00 CEST | Press release
Approval based on three phase 2 trials of Daiichi Sankyo and AstraZeneca’s Enhertu that demonstrated clinically meaningful responses across a broad range of tumors Enhertu now approved for six indications in the EU Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from subgroups of patients with HER2 positive (IHC 3+) tumors across thr
Beerenberg Prevails in Patent Case Against Aspen Aerogels29.6.2026 07:00:00 CEST | Press release
The ruling confirms that Beerenberg did not infringe Aspen Aerogels’ patents. The Korean Patent Court has invalidated three of Aspen Aerogels’ patents related to improved hydrophobic aerogel material. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260628192007/en/ Beerenberg delivers high-end insulation solutions built for performance, reliability, and long-term value. (Photo: Beerenberg) The ruling confirms the conclusion of the Intellectual Property Trial and Appeal Board (IPTAB) that the patents did not meet the necessary requirements for patentability. Beerenberg, which specializes in high-end insulation products, welcomes the court’s decision. “We are pleased that the case has now been concluded and that any uncertainty regarding the infringement claims has been removed,” says CEO Arild Apelthun. About Beerenberg Beerenberg has delivered cost-efficient solutions to a wide range of industrial enterprises for 49 years. Th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom